Sugammadex Fresenius Kabi

Maa: Euroopan unioni

Kieli: englanti

Lähde: EMA (European Medicines Agency)

Osta se nyt

Pakkausseloste Pakkausseloste (PIL)
21-07-2022
Valmisteyhteenveto Valmisteyhteenveto (SPC)
21-07-2022

Aktiivinen ainesosa:

sugammadex sodium

Saatavilla:

Fresenius Kabi Deutschland GmbH

ATC-koodi:

V03AB35

INN (Kansainvälinen yleisnimi):

sugammadex

Terapeuttinen ryhmä:

All other therapeutic products

Terapeuttinen alue:

Neuromuscular Blockade

Käyttöaiheet:

Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Valtuutuksen tilan:

Authorised

Valtuutus päivämäärä:

2022-07-15

Pakkausseloste

                                30
B.
PACKAGE LEAFLET
31
PACKAGE LEAFLET: INFORMATION FOR THE USER
SUGAMMADEX FRESENIUS KABI 100
MG/ML SOLUTION FOR INJECTION
sugammadex
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE
BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have further questions, ask your anaesthetist or doctor.
•
If you get any side effects, talk to your anaesthetist or other
doctor. This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Sugammadex Fresenius Kabi is and what it is used for
2.
What you need to know before Sugammadex Fresenius Kabi is given
3.
How Sugammadex Fresenius Kabi is given
4.
Possible side effects
5.
How to store Sugammadex Fresenius Kabi
6.
Contents of the pack and other information
1.
WHAT SUGAMMADEX FRESENIUS KABI IS AND WHAT IT IS USED FOR
WHAT SUGAMMADEX FRESENIUS KABI IS
Sugammadex Fresenius Kabi contains the active substance sugammadex.
Sugammadex is considered
to be a
_selective relaxant binding agent _
since it only works with specific muscle relaxants,
rocuronium bromide or vecuronium bromide.
WHAT SUGAMMADEX FRESENIUS KABI IS USED FOR
When you have some types of operations, your muscles must be
completely relaxed. This makes it
easier for the surgeon to do the operation. For this, the general
anaesthetic you are given includes
medicines to make your muscles relax. These are called
_muscle relaxants_
, and examples include
rocuronium bromide and vecuronium bromide. Because these medicines
also make your breathing
muscles relax, you need help to breathe (artificial ventilation)
during and after your operation until you
can breathe on your own again.
Sugammadex is used to speed up the recovery of your muscles after an
operation to allow you to breathe
on your own again earlier. It does this by combining with the
rocuronium bromide or vecuronium
bromide in your body. It can be used in adults whenever rocuronium
bromide or vecuronium bromide is
used and in 
                                
                                Lue koko asiakirja
                                
                            

Valmisteyhteenveto

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Sugammadex Fresenius Kabi100 mg/mL solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 mL contains sugammadex sodium equivalent to 100 mg sugammadex.
Each vial of 1 mL contains sugammadex sodium equivalent to 100 mg
sugammadex.
Each vial of 2 mL contains sugammadex sodium equivalent to 200 mg
sugammadex.
Each vial of 5 mL contains sugammadex sodium equivalent to 500 mg
sugammadex.
Excipient(s) with known effect
Contains up to 9.7 mg/mL sodium (see section 4.4).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection (injection).
Clear and colourless to slightly yellow solution, free from visible
particles.
The pH is between 7 and 8 and osmolality is between 300 and 500
mOsm/kg.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Reversal of neuromuscular blockade induced by rocuronium or vecuronium
in adults.
For the paediatric population: sugammadex is only recommended for
routine reversal of rocuronium
induced blockade in children and adolescents aged 2 to 17 years.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Sugammadex should only be administered by, or under the supervision of
an anaesthetist.
The use of an appropriate neuromuscular monitoring technique is
recommended to monitor the recovery
of neuromuscular blockade (see section 4.4).
The recommended dose of sugammadex depends on the level of
neuromuscular blockade to be reversed.
The recommended dose does not depend on the anaesthetic regimen.
Sugammadex can be used to reverse different levels of rocuronium or
vecuronium induced
neuromuscular blockade:
_Adults _
_ _
_Routine reversal: _
A dose of 4 mg/kg sugammadex is recommended if recovery has reached at
least 1-2 post-tetanic counts
(PTC) following rocuronium or vecuronium induced blockade. Median time
to recovery of the T
4
/T
1
ratio to 0.9 is around 3 minutes (see section 5.1).
3
A dose of 2 mg/kg sugammadex is recommended, if spontaneous recovery
has occurred
                                
                                Lue koko asiakirja
                                
                            

Asiakirjat muilla kielillä

Pakkausseloste Pakkausseloste bulgaria 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto bulgaria 21-07-2022
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta bulgaria 21-07-2022
Pakkausseloste Pakkausseloste espanja 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto espanja 21-07-2022
Pakkausseloste Pakkausseloste tšekki 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto tšekki 21-07-2022
Pakkausseloste Pakkausseloste tanska 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto tanska 21-07-2022
Pakkausseloste Pakkausseloste saksa 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto saksa 21-07-2022
Pakkausseloste Pakkausseloste viro 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto viro 21-07-2022
Pakkausseloste Pakkausseloste kreikka 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto kreikka 21-07-2022
Pakkausseloste Pakkausseloste ranska 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto ranska 21-07-2022
Pakkausseloste Pakkausseloste italia 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto italia 21-07-2022
Pakkausseloste Pakkausseloste latvia 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto latvia 21-07-2022
Pakkausseloste Pakkausseloste liettua 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto liettua 21-07-2022
Pakkausseloste Pakkausseloste unkari 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto unkari 21-07-2022
Pakkausseloste Pakkausseloste malta 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto malta 21-07-2022
Pakkausseloste Pakkausseloste hollanti 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto hollanti 21-07-2022
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta hollanti 21-07-2022
Pakkausseloste Pakkausseloste puola 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto puola 21-07-2022
Pakkausseloste Pakkausseloste portugali 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto portugali 21-07-2022
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta portugali 21-07-2022
Pakkausseloste Pakkausseloste romania 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto romania 21-07-2022
Pakkausseloste Pakkausseloste slovakki 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto slovakki 21-07-2022
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta slovakki 21-07-2022
Pakkausseloste Pakkausseloste sloveeni 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto sloveeni 21-07-2022
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta sloveeni 21-07-2022
Pakkausseloste Pakkausseloste suomi 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto suomi 21-07-2022
Pakkausseloste Pakkausseloste ruotsi 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto ruotsi 21-07-2022
Pakkausseloste Pakkausseloste norja 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto norja 21-07-2022
Pakkausseloste Pakkausseloste islanti 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto islanti 21-07-2022
Pakkausseloste Pakkausseloste kroatia 21-07-2022
Valmisteyhteenveto Valmisteyhteenveto kroatia 21-07-2022

Etsi tähän tuotteeseen liittyviä ilmoituksia